Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arbutus Biopharma Corp (NQ: ABUS ) 3.870 +0.040 (+1.04%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Arbutus Biopharma Corp < Previous 1 2 3 4 5 6 Next > Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts August 01, 2024 While the Arbutus layoffs represents a major overhaul operationally, the market has responded positively to ABUS stock. Here’s why. Via InvestorPlace Topics Workforce Exposures Layoff Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 01, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update July 18, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B June 06, 2024 From Barinthus Biotherapeutics Via GlobeNewswire Earnings Scheduled For February 29, 2024 February 29, 2024 Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. Via Benzinga Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels June 06, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure June 05, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Participate in Jefferies Global Healthcare Conference May 29, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Present Imdusiran Data at EASL Congress 2024 May 22, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value May 17, 2024 From Whitefort Capital Management, LP Via Business Wire Arbutus to Participate in Two Upcoming Investor Conferences May 07, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024 May 02, 2024 ABUS stock results show that Arbutus Biopharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update May 02, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 May 02, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update April 18, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire 3 Healthcare Stocks Short Sellers Are Prescribing for Trouble April 05, 2024 The healthcare industry is one of the most potent yet also one of the most competitive. This has short sellers out for blood. Via InvestorPlace Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge April 04, 2024 Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology. Via Benzinga Topics Intellectual Property Exposures COVID-19 Intellectual Property Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead April 04, 2024 Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth. Via Benzinga Topics Intellectual Property Exposures COVID-19 Intellectual Property Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna April 04, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim April 03, 2024 Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against Moderna in court. Via Benzinga Topics Intellectual Property Exposures COVID-19 Intellectual Property Arbutus to Participate in Two Upcoming Investor Conferences March 08, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update February 29, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update February 15, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Announces 2024 Corporate Objectives and Provides Financial Update January 08, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD November 09, 2023 From Barinthus Biotherapeutics Via GlobeNewswire Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting® November 09, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Present at Jefferies London Healthcare Conference November 08, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 07, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Announces CEO, William Collier, to Retire December 31, 2023 November 07, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update October 24, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.